ARA American Renal Associates Holdings Inc.

STOCK LOSS ALERT: Rosen Law Firm Reminds American Renal Associates Holdings, Inc. Investors of Important Deadline in Class Action - ARA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Renal Associates Holdings, Inc. securities (NYSE:ARA): (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016 of the important October 31, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for American Renal investors under the federal securities laws.

To join the American Renal class action, go to the firm’s website at http://www.rosenlegal.com/cases-946.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-946.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
26/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on American Renal Associates Holdings Inc.

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Third Quarter 2020 ...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the third quarter ended September 30, 2020. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below). Third Quarter 2020 Highlights (all percentage changes compare Q3 2020 to Q3 2019 unless noted): Patient service operati...

 PRESS RELEASE

American Renal Associates Enters Into Definitive Agreement to be Acqui...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (“ARA” or the “Company”), a leading provider of outpatient dialysis services, today announced that it has entered into a definitive agreement to be acquired by Innovative Renal Care, LLC (“IRC”), an affiliate of Nautic Partners, LLC (“Nautic”), a middle market private equity firm, in an all-cash transaction that values the Company at an aggregate enterprise valuation of approximately $853 million excluding non-controlling interest. Under the terms of the agreement, ARA shareholders will receive $11.50 per sh...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Settlement of Share...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the “Johnson Action”). The proposed settlement releases all claims asserted against the Company and the other named defendants in the Johnson Action without any liability o...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Second Quarter 2020...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the second quarter ended June 30, 2020. The Company also provided an update on its COVID-19 impact and affirmed its 2020 Adjusted EBITDA less noncontrolling interests (“Adjusted EBITDA-NCI”) Outlook. These updates are highlighted later in this release. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures ...

 PRESS RELEASE

American Renal Associates Holdings, Inc. Announces Second Quarter 2020...

BEVERLY, Mass.--(BUSINESS WIRE)-- American Renal Associates Holdings, Inc. (NYSE: ARA), a leading kidney care and dialysis services provider focused on partnering with local nephrologists, announced today that it will release its second quarter 2020 earnings results after the market close on Monday, August 10, 2020, to be followed by a conference call on Tuesday, August 11, 2020 at 9:00 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing (877) 407-8029, or for international callers (201) 689-8029. A replay will be available one hour after the call and can ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch